BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30006427)

  • 1. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
    Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
    J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
    JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
    van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional and Distant Outcomes in Women With cT1-3N1 Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Adjuvant Radiotherapy.
    Kozak MM; von Eyben R; Gutkin PM; Vemuri M; Jacobson CE; Karl JJ; Walck E; Marquez C; Horst KC
    Clin Breast Cancer; 2021 Aug; 21(4):373-382. PubMed ID: 33766533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Huang Z; Zhu L; Huang XB; Tang Y; Rong QL; Shi M; Wang WH; Tie J; Shen LF; Chen JY; Zhang J; Wu HF; Cheng J; Liu M; Tan YT; Ma CY; Wang SL; Li YX
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1030-1039. PubMed ID: 32585337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Discordance in Primary Tumor and Lymph Node Response After Neoadjuvant Therapy in Breast Cancer.
    Fleming CA; McCarthy K; Ryan C; McCarthy A; O'Reilly S; O'Mahony D; Browne TJ; Redmond P; Corrigan MA
    Clin Breast Cancer; 2018 Apr; 18(2):e255-e261. PubMed ID: 29246703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
    Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status.
    Zetterlund L; Celebioglu F; Hatschek T; Frisell J; de Boniface J
    Br J Surg; 2021 May; 108(5):583-589. PubMed ID: 34043772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis.
    Fayanju OM; Ren Y; Suneja G; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Force J; Hyslop T; Hwang ES
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):377-389. PubMed ID: 31678225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Go J; Ahn JH; Park JM; Choi SB; Kim JY; Park HS; Kim SI; Park BW; Park S
    Ann Surg Oncol; 2023 Nov; 30(12):7060-7068. PubMed ID: 37537485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.
    Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
    J Pathol Transl Med; 2017 Jan; 51(1):69-78. PubMed ID: 28013533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
    Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
    Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
    Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
    Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
    Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.